SEC Form 4 · accession 0001209191-17-045994
Dare Bioscience, Inc. · DARE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lisa Walters-Hoffert
Officer — Chief Financial Officer
Period of report
Jul 19, 2017
Accepted (ET)
Jul 21, 2017 · 5:12 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001401914
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jul 19, 2017 | A | 443,512 | — | A | 443,512 | I | By The Lisa Walters-Hoffert Survivor's Trust dated October 31, 2002 |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1In exchange for the issuance of shares of common stock and options to purchase shares of common stock of Dare Bioscience, Inc. (the "Corporation"), the Corporation acquired all of the issued and outstanding shares of common stock of Dare Bioscience Operations, Inc. ("Dare Operations") pursuant to the terms of a Stock Purchase Agreement, dated March 19, 2017, by and between the Corporation, Dare Operations and certain equityholders of Dare Operations party thereto, as filed with the Securities and Exchange Commission on Form 8-K on March 20, 2017 (such exchanges and issuances, the "Transaction").
- F2The shares reported reflect the 10 for 1 reverse stock split effected by the Corporation on July 20, 2017. These shares were received in connection with the Transaction in exchange for 2,184,823 shares of Dare Operations common stock. On the effective date of the Transaction, the closing price of the common stock of the Corporation, as reported on The Nasdaq Capital Market, was $6.56 per share (on a post-split basis). Each share of common stock of Dare Operations was cancelled and exchanged for the right to receive 0.2029969047 shares of common stock of the Corporation (on a post-split basis).